Pharming Group to participate in February investor conference
Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025
Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the 'Upcoming Events' and 'News' sections of Pharming's website.
For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at [email protected] or your Oppenheimer representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
T: +1 (908) 705 1696
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Clearwater Analytics Strengthens Outlook Through Bloomberg Alliance and Analyst Support
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the . The company witnesses its Buy rating maintained by analysts following a strategic partnership with Bloomberg. A wide shot of a large financial data center. Headquartered in Idaho, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) offers a cloud-native SaaS platform for automated investment data aggregation, reconciliation, accounting, reporting, and analytics. The company's solutions support over $8.8 trillion in assets daily. In addition to insurers, asset managers, and corporates, the company also serves government clients. On July 9, 2025, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) announced entering into a strategic partnership with Bloomberg to deliver a front-to-back investment solution using an open and modular approach for asset owners and asset managers. The partnership involves combining Bloomberg's front-office workflows with Clearwater's back-office accounting platform, thereby achieving efficiency in streamlining investment management operations. The collaboration with Bloomberg also places the company favorably in front-office Request for Proposal discussions. On June 11, 2025, Oppenheimer lowered the price target on the stock from $40 to $36 while maintaining an Outperform rating. Morgan Stanley reflects the sentiment by maintaining a Buy rating and a price target of $36. Investors interested in purchasing the stock must note the beta of Clearwater Analytics Holdings, Inc. (NYSE:CWAN), which currently stands at 0.73 alongside an EPS growth of 24.07% projected for the next 5 years. While we acknowledge the potential of CWAN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Texas Instruments Stock Nosedives After Shock Earnings Outlook
July 23 - Texas Instruments (NASDAQ:TXN) shares fell more than 10% in pre-market trading Wednesday after its third-quarter revenue outlook came in below Wall Street estimates, despite delivering stronger-than-expected results for the second quarter. Warning! GuruFocus has detected 11 Warning Signs with TXN. The chipmaker reported Q2 revenue of $4.45 billion, topping the $4.36 billion analyst consensus, and earnings per share of $1.41, also ahead of the expected $1.35. Net income rose 15% year over year to $1.3 billion. Analog chip revenue, the company's core segment, climbed 18% to $3.5 billion, exceeding projections. The growth was driven by demand from the automotive and industrial markets. However, Texas Instruments guided Q3 revenue in the range of $4.45 billion to $4.8 billion, with a midpoint slightly below the $4.59 billion consensus. The company also forecast EPS between $1.36 and $1.60, bracketing analysts' $1.50 average. Shares had been up 15% year to date before the report, helped by broader enthusiasm in the semiconductor sector. The company recently committed $60 billion toward U.S. chip factory expansion, a plan supported by the Trump administration's domestic tech push. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Rezolve AI PLC (RZLV) To Support Stablecoin Transactions
Rezolve AI (NASDAQ:RZLV) is one of the top AI stocks with tremendous upside potential. On July 21, the company confirmed that its platform is well-positioned to support stablecoin transactions following the passing of the GENIUS Act. The passing of the GENIUS Act is welcome, as Rezolve AI has carved a niche in offering artificial intelligence-powered solutions that enhance customer engagement while optimizing revenue. Its platform delivers tools that utilize AI to improve the digital experience and decision-making processes. 'The GENIUS Act is expected to transform stablecoins from speculative assets into regulated digital dollars,' said Daniel M. Wagner, CEO of Rezolve AI. 'Tether's commitment to compliance is a milestone, and Rezolve believes it is ready to connect this new liquidity to the real economy.' The Rezolve AI Brain Suite platform is already integrated into Microsoft Azure and Google Cloud infrastructure to support wallet-based payments. The Microsoft and Google integrations enable enterprise-grade scalability and deployment, therefore exposing the company to a $30 trillion market globally. Rezolve AI (NASDAQ:RZLV) is a pure-play artificial intelligence (AI) company that develops proprietary Large Language Models (LLMs) tailored for the retail sector. Its Brain Suite of AI solutions helps retailers deepen customer engagement, streamline operations, and boost sales with scalable AI-driven tools. While we acknowledge the potential of RZLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
